Neonatal screening for cystic fibrosis in the trent region (UK): Two- stage immunoreactive trypsin screening compared with a three-stage protocol with DNA analysis as an intermediate step

Journal of Medical Screening

Volumn 4, Issue 1, 1997, Pages 23-28

  Pollitt, R J ^a   Dalton, A ^b   Evans, S ^b   Hughes, H N ^b   Curtis, D ^b  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b Centre for Human Genetics   (United Kingdom)

Author keywords

Cystic fibrosis; DNA based diagnosis; Neonatal screening

Indexed keywords

DNA; TRYPSIN;

ARTICLE; BLOOD SAMPLING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA DETERMINATION; ENZYME BLOOD LEVEL; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; SWEAT TEST; UNITED KINGDOM;

EID: 0031402353     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1177/096914139700400109     Document Type: Article

References (29)

1. Wilcken B. Newborn screening for cystic fibrosis: its evolution and a review of the current situation. Screening 1993;2:43-62.
2. Farrell PM. Cystic fibrosis neonatal screening - a continuing dilemma, especially in North America. Screening 1993;2: 63-7.
3. Balnaves ME, Bonacquisto L, Francis I, Glazner J, Forrest S. The impact of newborn screening on cystic fibrosis testing in Victoria, Australia. J Med Genet 1995;32:537-42.
4. Chatfield S, Owen G, Ryley HC, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child 1991;66:29-33.
5. Wilcken B, Chalmers G. Reduced mortality in patients with cystic fibrosis detected by neonatal screening. Lancet 1985; 2:1319-21.
6. Marcus MS, Sondel SA, Farrell PM, et al. Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention. Am J Clin Nutr 1991;54:578-85.
7. Dankert-Roelse JE, Meerman GJ. Long-term prognosis in patients with cystic fibrosis in relation to early detection by neonatal screening and centre treatment. Thorax 1995;50: 712-8.
8. Littlewood LM, Littlewood AK, McLaughlin S, Shapiro L, Connolly S. 20 years of continuous neonatal screening in one hospital: progress of the 37 patients and their families. Pediatr Pulmonol 1995;suppl 12:284.
9. Waters D, Wilcken B, Irwig L, Simpson J, van Aspern P, Gaskin K. Clinical outcomes from newborn screening for cystic fibrosis in NSW (abstract). J Paediatr Child Health 1996;32:A16.
10. Heeley AF, Bangert SK. The neonatal detection of cystic fibrosis by measurement of immunoreactive trypsin in blood. Ann Clin Biochem 1992;29:361-76.
11. Travert G. Analyse de l'experience mondiale de dépistage néonatal de la mucoviscidose par la dosage de la trypsine immunoreactive sanguine. Mucoviscidose. Dépistage Néonatal et Prise en Charge Précoce, Caen: Université de Caen, 1998, 1-23.
12. Dhondt JL, Farriaux JP, Briard ML, Boschetti R, Frézal J. Results of pilot screening activities in the French neonatal screening program - cystic fibrosis, congenital adrenal hyperplasia and sickle cell disease. Screening 1993;2:87-97.
13. Ranieri E, Ryall RG, Morris CP, et al. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene assay. BMJ 1991;302:1237-40.
14. Ranieri E, Lewis BD, Gerace RL, et al. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen: four years' experience. BMJ 1994;308:1469-72.
15. Spence WC, Paulus-Thomas J, Orenstein DM, Naylor EW. Neonatal screening for cystic fibrosis: addition of molecular diagnostics to increase specificity. Biochemistry Medicine and Metabolic Biology 1993;49:200-11.
16. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis: comparison of screening protocols. Am J Hum Genet 1993; 52:616-26.
17. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 1995;127: 965-70.
18. Larsen J, Campbell S, Faragher EB, et al. Cystic fibrosis screening in nepnates - measurement of immunoreactive trypsin and direct genotype analysis for the ΔF508 mutation. Eur J Pediatr 1994;153:569-73.
19. Heeley AF, Heeley ME, King DN, Kuzemko JA, Walsh MP. Screening for cystic fibrosis by dried blood spot trypsin assay. Arch Dis Child 1982;57:18-21.
20. Nørgaard-Pedersen B, Høgdall E, Iitiä A, Arends J, Dahlen P, Vuust J. Immunoreactive trypsin and a comparison of two ΔF508 mutation analyses in newborn screening for cystic fibrosis: an anonymous pilot study in Denmark. Screening 1993;2:1-11.
21. Laroche D, Travert G. Abnormal frequency of the ΔF508 mutation in neonatal hypertrypsinaemia. Lancet 1991;337: 55.
22. Lucotte G. Perignon J-L, Lenoir G. Transient neonatal hypertrypsinaemia as a test for AF508 heterozygosity. Lancet 1991;337:988.
23. Schwarz MT, Malone GM, Haworth A, et al. Cystic fibrosis mutation analysis: report from 22 UK regional genetics laboratories. Hum Mutat 1995;6:326-33.
24. Fitzgerald D, Van Aspern P, Henry R, et al. Delayed diagnosis of cystic fibrosis in children with a rare genotype (ΔF508/R117H) J Paediatr Child Health 1995;31:168-71.
25. Stewart B, Zabner J, Shuber AP, Welsh MJ, McCray PB. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med 1995;151:899-903.
26. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994;331:974-80.
27. Patrizio P, Asch RH, Handelin B, Silber SJ. Aetiology of congenital absence of vas deferens: genetic study of three generations. Hum Reprod 1993;8:215-20.
28. Wilson JAG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organisation, 1968. (Public health papers No 34.)
29. Working party of the Clinical Genetics Society. The genetic testing of children. J Med Genet 1994;31:785-97.